BC Innovations | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BC Week In Review | Aug 18, 2017
Clinical News

MAGEA3 T cell therapy safe, leads to responses in NCI study

In a study published in the Journal of Clinical Oncology , researchers at NIH's NCI and colleagues reported that a major histocompatibility complex (MHC) class II-restricted melanoma-associated antigen A3 (MAGEA3)-targeted T cell receptor (TCR) T cell...
BC Extra | Aug 17, 2017
Clinical News

MAGEA3 T cell therapy safe, leads to responses in NCI study

In a study published in the Journal of Clinical Oncology , researchers at NIH's NCI and colleagues reported that a melanoma-associated antigen A3 ( MAGEA3 )-targeted T cell receptor (TCR) T cell therapy from Kite Pharma Inc....
BC Innovations | Jul 20, 2017
Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
BC Week In Review | Jan 13, 2017
Company News

Kite, Fosun deal

Kite and Fosun formed the JV Fosun Pharma Kite Biotechnology Co. Ltd. (Shanghai, China) to develop Kite's lead chimeric antigen receptor (CAR) T cell immunotherapy candidate, axicabtagene ciloleucel (KTE-C19), in China. The JV may also...
BC Week In Review | Jan 13, 2017
Company News

Kite, Daiichi Sankyo deal

Kite granted Daiichi Sankyo rights in Japan to develop and commercialize chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (KTE-C19). Kite will receive $50 million up front and is eligible for up to $200...
BC Week In Review | May 14, 2012
Clinical News

Immunocore preclinical data

In a mouse xenograft model of melanoma, 0.01 mg/kg ImmTAC-MAGE given every other day for 10 doses significantly inhibited tumor growth at day 22 through day 41 vs. vehicle-treated controls (p<0.001 for all time points)....
Items per page:
1 - 7 of 7